The B cell-specific transcription factor BACH2 is required for affinity maturation of B cells. Here we show that Bach2-mediated activation of p53 is required for stringent elimination of pre-B cells that failed to productively rearrange immunoglobulin V H -DJ H gene segments. After productive V H -DJ H gene rearrangement, pre-B cell receptor signaling ends BACH2-mediated negative selection through B cell lymphoma 6 (BCL6)-mediated repression of p53. In patients with pre-B acute lymphoblastic leukemia, the BACH2-mediated checkpoint control is compromised by deletions, rare somatic mutations and loss of its upstream activator, PAX5. Low levels of BACH2 expression in these patients represent a strong independent predictor of poor clinical outcome. In this study, we demonstrate that Bach2 +/+ pre-B cells resist leukemic transformation by Myc through Bach2dependent upregulation of p53 and do not initiate fatal leukemia in transplant-recipient mice. Chromatin immunoprecipitation sequencing and gene expression analyses carried out by us revealed that BACH2 competes with BCL6 for promoter binding and reverses BCL6-mediated repression of p53 and other cell cycle checkpoint-control genes. These findings identify BACH2 as a crucial mediator of negative selection at the pre-B cell receptor checkpoint and a safeguard against leukemogenesis. npg
In mice, bone marrow progenitor cells produce approximately 10 million pre-B cells daily 1 . Newly formed pre-B cells, however, are destined to die unless they productively rearrange V H -DJ H gene segments and are rescued by pre-B cell receptor signals and transition into the long-lived peripheral B cell pool 2, 3 . The decision of a pre-B cell carrying a newly rearranged immunoglobulin heavy chain to undergo death (negative selection) or survival (positive selection) is made at the pre-B cell receptor checkpoint. To maintain the fidelity of the B cell repertoire, negative selection of pre-B cells with nonfunctional heavy chains must precede the survival of those with functional rearrangements. We recently identified the transcriptional repressor BCL6 as a crucial survival factor that rescues pre-B cells that have productively rearranged V H -DJ H gene segments and emerged from the pre-B cell receptor checkpoint 4, 5 . However, the mechanisms leading to the clearance of other pre-B cells that failed to productively rearrange V H -DJ H gene segments and thus lack expression of the pre-B cell receptor are poorly understood.
RESULTS

Bach2 induces Arf and p53 during early B cell development
To identify factors that mediate negative selection at the pre-B cell receptor checkpoint in humans, we studied gene expression changes during human B cell development at the pro-B cell to pre-B cell transition 6 . We identified 18 genes with specific upregulation at the pre-B cell receptor checkpoint, including components of the pre-B cell receptor itself (IGLL1 and VPREB1), effectors of V H -DJ H recombination (RAG1, RAG2 and DNTT) and mediators of survival signaling (Supplementary Fig. 1 ). We next studied gene expression changes at the pre-B cell receptor checkpoint in mice under two experimental conditions: initiation of V(D)J recombination after inducible activation of Pax5 (ref. 7) and inducible expression of productively rearranged V H -DJ H encoding a functional immunoglobulin µ heavy chain (µHC), which initiates pre-B cell receptor signaling 5 (Fig. 1a) . We reasoned that pre-B cell receptor checkpoint control should occur between these two events. Indeed, we found that Pax5-mediated initiation of V(D)J recombination was concident with strong upregulation of recombination activating gene 1 (Rag1) and Rag2 and caused upregulation of Arf and p53 and Bach2 (refs. 8,9) . By contrast, inducible activation of µHC expression induced expression of Bcl6, a transcriptional repressor of Arf and p53 ( Fig. 1a-c) .
Bcl6-mediated repression of Arf and p53 is needed to rescue µHC + pre-B cells once they have passed the pre-B cell receptor checkpoint 4, 5 . Consistent with our findings in human B cell differentiation ( Supplementary Fig. 1) , we found high expression of Bach2 before (pro-B and pre-BI cells) and high expression of Bcl6 after (pre-BII cells) passage of the pre-B cell receptor checkpoint in mice (Fig. 1d) . These findings imply that Bach2 may contribute to the negative selection of pre-B cells that failed to productively rearrange V H -DJ H gene segments at the pre-B cell receptor checkpoint. To test this hypothesis, we assayed pre-B cell receptor checkpoint control in pro-B and pre-BI cells from Bach2 −/− mice 9 and wild-type control mice under the two experimental conditions described above. Activation of GFP-tagged Pax5 induced the accumulation of Arf and p53 and resulted in rapid elimination of Bach2 +/+ but not Bach2 −/− pro-B and pre-BI cells ( Fig. 1e-g) .
Bcl6 reverses Bach2-induced activation of Arf and p53
Previous studies by our group identified Bcl6 as a strong transcriptional repressor of Arf and p53 in normal pre-B cells 4 and in pre-B acute lymphoblastic leukemia (ALL) 10 . Of note, ChIP-seq analysis and quantitative ChIP (qChIP) validation revealed that both BCL6 and BACH2 bind to overlapping promoter regions of CDKN2A (ARF), TP53 (P53) and other checkpoint regulators (CDKN1A (P21), CDKN1B (P27), GADD45A and GADD45B) ( Fig. 2a and  Supplementary Figs. 2 and 3) . We therefore tested the hypothesis that BACH2 and BCL6 compete for binding to promoter regions of checkpoint regulator genes and that the ratio between the two proteins determines negative (more BACH2 than BCL6) and positive (less BACH2 than BCL6) selection events at the pre-B cell receptor checkpoint ( Fig. 2 and Supplementary Figs. 4 and 5) . Binding of either BCL6 or BACH2 to CDKN2A and TP53 promoters affects gene expression in opposite directions: mRNA and protein levels of Arf and p53 are significantly reduced in the absence of Bach2 but are strongly increased in the absence of Bcl6 ( Fig. 2c,d,f and Supplementary  Fig. 6 ) or after inducible overexpression of Bach2 ( Fig. 2c and Supplementary Fig. 4 ). Likewise, mRNA levels of the p53-dependent tumor suppressor Btg2 (ref. 11) were reduced by >20-fold in the absence of Bach2 but were increased by threefold in the absence of Bcl6 ( Fig. 2f and Supplementary Fig. 4 ). To test whether Bach2 negatively regulates the ability of Bcl6 to bind to Cdkn2a and Tp53 promoters, we performed ChIP experiments with Bcl6 −/− (negative control), Bach2 +/+ and Bach2 −/− mouse pre-B cells. Binding of Bcl6 to Cdkn2a and Tp53 promoters was significantly increased in Bach2 −/− compared to Bach2 +/+ cells ( Fig. 2e and Supplementary Fig. 5 ). Gene expression analysis of a subset of common Bach2 and Bcl6 target genes revealed that Bcl6 and Bach2 affect the gene expression levels of checkpoint regulators, including Cdkn2a, Tp53, Gadd45b, Btg1 and Btg2, in opposite directions (Fig. 2d,f and Supplementary Fig. 6 ). These findings collectively indicate that the balance between Bcl6 Bach2 (e,f) GFP + cells monitored (on days 1 and 10) by flow cytometry in transformed pro-B and pre-BI cells from Bach2 −/− and wild-type (Bach2 +/+ ) mice that were transduced with GFP-tagged Pax5 or empty vector controls (n = 3 for each condition; all P values were calculated using Student's t test). (g) Protein expression of Arf and p53, determined by western blotting with β-actin (Actb) as the loading control, in Bach2 +/+ and Bach2 −/− pro-B and pre-BI cells that were transduced with Pax5-GFP or the empty vector control. Error bars (b,d,f), s.d. and Bach2 determines the repression or transcriptional activation of Cdkn2a, Tp53 and related checkpoint molecules.
Bach2 mediates V-DJ recombination
We measured the functional consequences of Bach2 deficiency at the pre-B cell receptor checkpoint in Bach2 −/− and wild-type mice. Using a classical pre-B cell differentiation model based on tyrosine kinase inhibition (with imatinib) of BCR-ABL1-transformed pre-B cells 12, 13 , we studied gene expression changes after differentiation of Bach2 −/− and Bach2 +/+ pre-BI cells (Fig. 3a) . In this analysis, Bach2 deficiency was associated with increased expression of the early progenitor antigen Ly6a (also known as Sca-1) and reduced expression of the pre-B cell antigen interleukin-2 receptor α (Il-2ra, also known as CD25; Fig. 3a,b) . Notably, mRNA levels of Rag1 and Rag2, which are crucial effectors of V(D)J recombination, were reduced by ~20-fold in pre-BI cells from Bach2 −/− mice. Likewise, imatinib-induced differentiation resulted in strong upregulation of Rag1 and Rag2 expression in Bach2 +/+ pre-BI cells, as has been described 4,12,13 , but did not upregulate Rag1 and Rag2 beyond baseline levels in Bach2 −/− cells ( Fig. 3c) .
Inducible overexpression of Bach2 was sufficient to drive Rag1 and Rag2 upregulation (Fig. 3d) , and single-locus ChIP analysis revealed that BACH2 binds RAG1 and RAG2 promoters, and this binding was enhanced by treatment with imatinib ( Fig. 3e) .
To test whether defective expression of Rag1 and Rag2 results in impaired V(D)J recombination activity, we transduced Bach2 −/− and Bach2 +/+ pre-BI cells with a V(D)J recombination signal sequence (RSS) substrate. Consistent with the greatly increased expression of Rag1 and Rag2, imatinib treatment resulted in a sixfold increase of baseline recombination of the RSS substrate in Bach2 +/+ pre-B cells. In contrast, imatinib-induced V(D)J recombination activity was reduced by 20-fold in Bach2 −/− pre-BI cells as compared to wild-type cells ( Fig. 3f and Supplementary Fig. 7 ).
Bach2 is required for clearance of nonfunctional pre-B cells We next studied the composition of B cell-progenitor populations in bone marrows and spleens of Bach2 +/+ and Bach2 −/− mice. The total numbers of CD19 + B220 + B cells were only slightly reduced in the bone marrow and spleens of Bach2 −/− mice ( Fig. 3g and Supplementary Fig. 8 ). Whereas pre-B cells from Bach2 +/+ bone marrow were stringently selected for productive in-frame V H -DJ H gene rearrangements, pre-B cells from Bach2 −/− bone marrow lacked selection for V H -DJ H junctions with coding capacity ( Fig. 3g and Supplementary Fig. 8 ). On the basis of random V(D)J recombination, only one in three pre-B cell clones should achieve in-frame rearrangements and coding capacity for a functional pre-B cell receptor. Effective negative pre-B cell selection causes elimination of cells with nonfunctional out-of-frame V H -DJ H rearrangements and thus results in a length distribution of V H -DJ H junctions with size peaks that are spaced by three nucleotides 14 . Fragment length analysis revealed a peak-size distribution of V H -DJ H junctions that were selected for multiples of 3 bp among Bach2 +/+ cells as compared to the random distribution in Bach2 −/− cells ( Fig. 3g and Supplementary Fig. 8 ). Sequence analysis of V H -DJ H junctions confirmed that out-of-frame V H -DJ H rearrangements were stringently cleared from the repertoire in Bach2 +/+ pre-B cells, as
Bcl6 opposed to the accumulation of a large fraction of clones with nonfunctional rearrangements seen in Bach2 −/− pre-B cells ( Fig. 3g and Supplementary Fig. 8 ).
To test whether activation of Bach2 downstream of Pax5 is sufficient to clear the pre-B cell repertoire of nonfunctional V H -DJ H rearrangements, we developed a vector system for inducible npg expression of Bach2. We transduced Il-7-dependent Bach2 +/+ and Bach2 −/− pre-B cells with a 4-hydroxytamoxifen (4-OHT)-inducible Bach2-ER T2 vector and an empty vector control, ER T2 . We then treated the cells with 4-OHT for 24 h and performed a sequence analysis of V H -DJ H junctions ( Fig. 3h and Supplementary Figs. 9 and 10) .
Although inducible overexpression of Bach2 had no statistically significant effect on the repertoire composition of Bach2 +/+ pre-B cells, inducible Bach2 reconstitution in Bach2 −/− pre-B cells resulted in the rapid elimination of clones carrying nonfunctional V H -DJ H rearrangements ( Fig. 3h and Supplementary Fig. 10 ). We conclude that Bach2 is required and sufficient for the stringent clearance of pre-B cells that failed to productively rearrange V H -DJ H segments at the pre-B cell receptor checkpoint.
Bach2 mediates tumor suppression in pre-B ALL In a high-throughput screen for retroviral integrations in mouse pre-B cell leukemia (using the Retroviral Tagged Cancer Gene Database, http://variation.osu.edu/rtcgd/), we found Bach2 introns 1-3 as common integration sites ( Supplementary Fig. 11 ), raising the possibility that Bach2 functions as a tumor suppressor in pre-B ALL. We therefore tested whether BACH2 affects the survival and proliferation of human pre-B ALL cells. To this end we transduced xenografts from clinically derived Philadelphia chromosome (Ph) + ALL cells with either a vector for Bach2 or an empty vector control. Primary Ph + ALL cells carrying GFP-tagged Bach2 were rapidly depleted (Fig. 4a,b and Supplementary Fig. 12 ). Although all Ph + ALL cells that we examined expressed P53 protein, in six of ten patient-derived xenografts, the Ph + ALL cells had low basal expression of ARF ( Fig. 4c) . Despite low ARF expression, the Ph + ALL cells underwent cell death as a result of Bach2 overexpression (Fig. 4b) .
Although BACH2 is required for the upregulation of both ARF and TP53, these findings indicate that BACH2 induces cell death in Ph + ALL cells independently of ARF.
To test the requirements of Arf and p53 downstream of Bach2 in a genetic experiment, we transduced Cdkn2a +/+ Tp53 +/+ (WT), Cdkn2a −/− and Tp53 −/− pre-B ALL cells with GFP-tagged Bach2 or an empty vector control ( Fig. 4d,e ). Whereas Bach2 caused rapid elimination of Cdkn2a −/− and wild-type leukemia cells, the effect of Bach2 on Tp53 −/− leukemia cells was delayed and was substantially diminished ( Fig. 4e and Supplementary Fig. 13 ). We conclude that p53 is an important effector of Bach2-mediated cell death, whereas Arf is dispensable. The results of our Arf and p53 western blot analysis ( Fig. 4c ) agree with previous findings that defects of p53 are rare in Ph + ALL, whereas deletions of ARF are frequent (52%) 15 .
To identify potential defects in Bach2 function in human leukemia, we analyzed leukemic blasts from 83 individuals with Ph + ALL (Eastern Cooperative Oncology Group (ECOG) 2993) and pre-B cells from 12 normal bone marrow samples with the HpaII tiny fragment enrichment by ligation-mediated PCR (HELP) assay for promoter methylation (log(HpaII/MspI)) 16 of the BACH2 gene. The BACH2 promoter was more hypermethylated in Ph + ALL cells as compared to normal human bone marrow pre-B cells (n = 83 Ph + ALL cells, P = 0.0026). In addition, sequence analysis of the BACH2 coding region in primary Ph + ALL samples revealed BACH2 BTB domain missense mutations in two of the ten individuals studied (Supplementary Fig. 14) . Given that p53 is intact in most Ph + ALLs, we conclude that inactivation of Bach2 upstream of p53 is an important and nonredundant lesion. npg PAX5 lesions result in defective BACH2 expression in pre-B ALL Our experiments described above showed that forced expression of Pax5 induces upregulation of Bach2 at the pre-B cell receptor checkpoint (Fig. 1a,b) . Recent studies have demonstrated that deletions and rearrangements of the PAX5 gene that result in dominantnegative fusion molecules occur in ~20% of cases of pre-B ALL 15, 17 . We therefore tested whether loss of PAX5 function results in transcriptional inactivation of BACH2 in human pre-B ALL cells. Whereas overexpression of wild-type PAX5 increased transcriptional activity of the BACH2 promoter, as measured by a luciferase reporter construct, overexpression of the dominant-negative PAX5-ETV6 fusion gene suppressed BACH2 promoter activity (Fig. 4f) . Likewise, mRNA levels of BACH2 were increased by expression of wild-type PAX5 but were decreased by the dominant-negative PAX5-C20orf112 and PAX5-ETV6 fusion genes 17 (Fig. 4g,h) . We next studied gene expression values for three BACH2 probe sets in 160 individuals with childhood pre-B ALL. Compared to the 54 individuals carrying either PAX5 deletions or somatic mutations of PAX5, BACH2 mRNA levels were significantly higher in the 106 individuals with pre-B ALL carrying wild-type PAX5 (Fig. 4i) . We conclude that BACH2 links PAX5 to activation of p53 and is therefore an important tumor suppressor in human pre-B ALL.
BACH2 expression as a predictor of ALL patient outcome BACH2 expression in ALLs carrying E2A (also called TCF3)-PBX1 and TEL (also called ETV6)-AML1 (also called RUNX1) gene rearrangements was similar to that in normal pre-B cells from healthy bone marrow donors. However, BACH2 mRNA levels were significantly lower in MLL (also called KMT2A)-AF4 (also called AFF1) (P = 0.01106) and Ph + ALL subtypes (P = 0.00203; Supplementary  Fig. 14) . We also studied BACH2 mRNA levels in matched sample pairs from 49 patients that had a relapse of leukemia after an initial successful treatment. Comparing matched sample pairs from the time of diagnosis and the subsequent relapse of leukemia, we found that BACH2 mRNA levels were substantially reduced in the relapse samples ( Fig. 5a and Supplementary Fig. 15 ). In addition, BACH2 expression levels at the time of diagnosis predicted minimal residual disease (MRD) in bone marrow biopsies taken on day 29 of treatment ( Fig. 5b) . Notably, loss of BACH2 expression correlated strongly with poor overall outcome among 207 patients with childhood ALL (Children's Oncology Group (COG) P9906). Patients with expression levels of BACH2 higher than the median level had a relapse-free survival rate of 77%, whereas patients with BACH2 expression levels lower than the median level had a relapse-free survival rate of 47% (Supplementary Fig. 16b ).
To study whether Bach2 mRNA levels are an independent predictor of clinical outcome, we performed multivariate analyses using three established predictors of poor clinical outcome as a reference: MRD, high white blood cell (WBC) counts (>100,000 µl −1 ) and deletion of the IKZF1 tumor suppressor 18 . Studying high-risk groups of patients on the basis of these three factors, we found that lower-than-median expression levels of BACH2 defined subgroups of patients with worse clinical outcome. Lowerthan-median expression levels of BACH2 at diagnosis predicted inferior clinical outcome for patients with positive MRD on day 29, for patients with WBC counts >100,000 µl −1 (Fig. 5c-e and  Supplementary Fig. 16 ) and for patients with deletion of IKZF1 (Supplementary Fig. 17 ).
Inverse relationship of BACH2 and BCL6 in ALL patient outcome Our data described above ( Figs. 1 and 2) demonstrated that both Bach2 and Bcl6 bind Cdkn2a and Tp53 promoters but inversely regulate mRNA levels of Arf and p53. Notably, the antagonistic function of BACH2 relative to BCL6 in the regulation of ARF, P53 and multiple other checkpoint genes is mirrored by their opposite association with clinical outcome. Whereas higher-than-median mRNA levels of BACH2 at the time of diagnosis predict favorable clinical outcome, the opposite is true for patients with ALL with higher-than-median BCL6 mRNA levels (COG P9906). Studying BACH2 and BCL6 mRNA levels in a bivariate analysis identified subgroups of patients with particularly favorable (BACH2 high BCL6 low ) and particularly poor (BACH2 low BCL6 high ) outcomes on the basis of the ratio of BACH2to-BCL6 mRNA levels (Fig. 5f) .
BACH2 is often deleted in B cell malignancies BACH2 is located at chromosome 6q15, and deletions of 6q encompassing 6q15 have been found in 32% of individuals with B celllineage ALL 19 . We therefore studied B cell-lineage ALL cell lines (n = 9) and individuals with primary ALL (n = 4) with 6q deletions by highresolution SNP analysis and found that BACH2 lies within a region of minimal deletion on 6q (Fig. 5g) .
Studying bone marrow samples from individuals with primary ALL at three time points, diagnosis, clinical remission and relapse of leukemia, we found that deletion of the BACH2 locus was acquired at the time of leukemia relapse in 3 of the 4 individuals studied and was pre-existing in the remaining individual ( Fig. 5g-j) . Fig. 18 ). These findings suggest that Bach2-mediated gene expression changes oppose a transcriptional program of survival (Stat5) and proliferation (Myc) downstream of BCR-ABL1 in Ph + ALL cells.
Consistent with this scenario, BCR-ABL1-transformed Bach2 −/− pre-B ALL cells are markedly less sensitive to inhibition of BCR-ABL1 using a tyrosine kinase inhibitor (TKI; imatinib) than their wildtype counterparts (Fig. 6a,b) . In the absence of Bach2, imatinibinduced apoptosis was reduced by threefold (Fig. 6a) , and the fraction of proliferating cells despite treatment with imatinib was increased by twofold ( Fig. 6b) . Whereas BCR-ABL1-transformed Bach2 +/+ cells were able to form colonies only after a lag phase of ~10 d, colony formation of Bach2 −/− pre-B ALL cells was significantly accelerated (Fig. 6c) .
Bach2 and Myc are mutually exclusive during transformation
Overexpression of the Myc proto-oncogene frequently leads to increased proliferation and malignant transformation. However, Mycdriven proliferation can be increased only within certain limits, and Myc alone is not sufficient to cause malignant growth 21, 22 . A number of failsafe mechanisms restrain Myc-induced proliferation and tumorigenesis 23 . These failsafe mechanisms are crucial for the termination npg of pre-malignant clones and therefore are a powerful safeguard against malignant transformation. By studying progressive transformation of pre-B cells in BCR-ABL1 transgenic mice in vivo, we found that the mRNA levels of Bach2 and Myc are inversely regulated. In wild-type and young (<30 d) nonleukemic BCR-ABL1 transgenic mice, mRNA levels of Bach2 were high, whereas mRNA levels of Myc were low. Between the ages of 30 and 120 d, BCR-ABL1 transgenic mice undergo progressive leukemic transformation 24 . Fully transformed leukemia cells express high levels of Myc and low levels of Bach2, whereas treatment of mice with a TKI (nilotinib) restored normal expression levels of Bach2 (high) and Myc (low; Fig. 6d ). We conclude that the expression levels of Bach2 and Myc are mutually exclusive during oncogenic transformation of pre-B cells.
Bach2 is a barrier against Myc-induced pre-B cell transformation
We next tested the hypothesis that Bach2 negatively regulates the susceptibility of pre-B cells to Myc-mediated transformation. In normal pre-B cells, high expression of Myc results in activation of Arf and p53 and oncogene-induced senescence [21] [22] [23] . Retroviral overexpression of Myc induced cell death and caused substantial toxicity in Bach2 +/+ but not Bach2 −/− pre-B cells (Fig. 6e,f and Supplementary Figs. 19 and 20) . These findings indicate that Bach2 strongly reduces the susceptibility of pre-B cells to malignant transformation by Myc.
A cell-cycle analysis revealed that overexpression of Myc in Bach2 +/+ pre-B cells increased the fraction of cells in S phase to a maximum threshold of about 50%. However, Myc overexpression in Bach2 −/− pre-B cells caused a further increase in proliferating cells, with about 70% of pre-B cells being in S phase (Supplementary Fig. 19b ). Consistent with these findings, overexpression of Myc in Bach2 +/+ pre-B cells resulted in activation of both Arf and p53. By contrast, p53 expression was very low in Bach2 −/− pre-B cells and was not increased by overexpression of Myc (Supplementary Fig. 19b ). We conclude that in the absence of Bach2, p53-dependent failsafe mechanisms are not activated, obviating the requirement of additional genetic lesions for leukemic transformation. npg Bach2 −/− pre-B cells with retroviral Myc-GFP. We then injected Myc-GFP + pre-B cells (Fig. 6e) into sublethally irradiated NSG recipient mice. Whereas Bach2 −/− Myc-GFP-transduced pre-B cells readily initiated fatal leukemia that killed the NSG recipient mice within 25 d, all NSG mice receiving Bach2 +/+ Myc-GFP pre-B cells were still healthy at 70 d after injection (Fig. 6g) . After 70 d, we euthanized and analyzed the mice in the surviving Bach2 +/+ Myc-GFP-transduced cohort together with the mice that received Bach2 −/− Myc-GFP pre-B cells. In contrast to mice injected with Bach2 −/− Myc-GFP pre-B cells, we found no CD19 + GFP + cells (which would indicate leukemia) in the mice receiving Bach2 +/+ Myc GFP pre-B cells ( Fig. 6h and  Supplementary Fig. 21) . PCR for GFP revealed small numbers of persisting leukemia cells in most of the surviving mice at 70 d after injection; however, the numbers of leukemia cells were 4-5 log 10 orders lower in the group injected with wild-type cells as compared to the mice injected with Bach2 −/− Myc-GFP pre-B cells (Fig. 6i) .
Bach2 loss facilitates leukemic transformation by Myc
DISCUSSION
We identified Bach2-mediated activation of p53 as a crucial mediator of pre-B cell receptor checkpoint control. During normal B cell development, Bach2 determines the stringency of negative selection of pre-B cell clones that failed to productively rearrange V H -DJ H gene segments. In addition, Bach2-mediated activation of p53 is an important failsafe mechanism in the termination of pre-malignant pre-B cell clones before they can complete malignant transformation. Thus, Bach2 limits pre-B cell proliferation and oncogene signaling through activation of p53. In both normal pre-B cells and pre-B ALL, Bach2-mediated activation of p53 is opposed by Bcl6, which is a potent transcriptional repressor of p53. Whereas inactivation of TP53 in ALL is rare, BACH2 is frequently inactivated in established pre-B ALL clones or at the time of leukemia relapse. Consistent with their opposing role in TP53 regulation and checkpoint control, the ratio of BACH2 (favorable) to BCL6 (poor) expression levels is also a strong predictor of clinical outcome in patients with ALL. Although BACH2 function cannot be reinstated in patients with ALL who carry BACH2 deletions, we propose that pharmacological inhibition of BCL6 (for example, with retroinverso BCL6 peptide inhibitor (RI-BPI)) will restore the balance of BACH2-to BCL6-mediated checkpoint control and relieve BCL6-mediated transcriptional repression of p53 (Supplementary Fig. 22) .
METHODS
Methods and any associated references are available in the online version of the paper. Tables 1 and 2) in compliance with the Institutional Review Boards of the University of California, San Francisco and the University of Southern California. We obtained informed consent from all participants. We cultured all primary human ALL samples on OP9 stromal cells in minimum essential medium (MEMα; Life Technologies) with GlutaMAX containing 20% FBS, 100 IU ml −1 penicillin, 100 µg ml −1 streptomycin and 1 mM sodium pyruvate at 37 °C in a humidified incubator with 5% CO 2 .
Extraction of bone marrow cells from mice. We extracted bone marrow cells from female young age-matched Bach2 +/+ and Bach2 −/− mice (less than 6 weeks of age) ( Supplementary Table 3 ). We obtained the bone marrow cells by flushing the cavities of the femurs and tibias with PBS. After filtration through a 70-µm filter and depletion of erythrocytes using a lysis buffer (BD PharmLyse, BD Biosciences), washed cells were either cryopreserved or used for further experiments.
In vivo model for Myc-driven leukemia. We first transformed Il-7-dependent pre-B cells from Bach2 +/+ and Bach2 −/− mice with a retroviral vector encoding Myc-internal ribosome entry site (IRES)-GFP (Myc-GFP). We then injected these cells intrafemurally into seven sublethally irradiated (250 cGy) female NOD/SCID/IL-2Rγ null (NOG) mice per group. We monitored the transplantrecipient mice for weight loss, hunched posture and inability to move as indicators of leukemia progression. For the group that showed signs of leukemia, we euthanized the mice after they became terminally ill. We euthanized the healthy group at day 70 after injection. We then stained the bone marrows and spleens isolated from all mice for B cell markers to ascertain that leukemia was the cause of death. In addition, we measured GFP expression levels in the bone marrow and spleen of each mouse to detect any minimal residual disease. All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Southern California and the University of California, San Francisco. We collected bone marrow cells from the above-mentioned groups of mice and retrovirally transformed them using BCR-ABL1 () in the presence of 10 ng ml −1 IL-7 (Peprotech) in RetroNectin (Takara)-coated Petri dishes as described below. We maintained all BCR-ABL1-transformed ALL cells derived from the bone marrow of the mice in Iscove's modified Dulbecco's medium (IMDM; Invitrogen) with GlutaMAX containing 20% FBS, 100 IU ml −1 penicillin, 100 µg ml −1 streptomycin and 50 µM 2-mercaptoethanol. BCR-ABL1-transformed ALL cells were propagated for short periods of time only, usually not longer than 2 months, to avoid acquisition of additional genetic lesions during long-term cell culture. All mice used in the study are listed in Supplementary Table 3 .
BCR-ABL1
TKIs. We obtained the TKIs imatinib and nilotinib from Novartis Pharmaceuticals and LC Laboratories, respectively. TKIs were dissolved in sterile distilled water and stored at −20 °C.
Western blotting. We lysed cells in CelLytic buffer (Sigma) supplemented with 1% protease inhibitor cocktail (Pierce). Protein samples were subsequently separated on NuPAGE (Invitrogen) 4-12% Bis-Tris gradient gels and transferred to polyvinylidene difluoride membranes (Immobilion, Millipore). For the detection of mouse and human proteins by western blot analysis, we used primary antibodies together with the WesternBreeze immunodetection system (Invitrogen). All antibodies used for western blotting and their corresponding dilutions are listed in Supplementary Table 4 .
Flow cytometry. We purchased all antibodies for flow cytometry measurements, as well as their respective isotype controls, from BD Biosciences ( Supplementary  Table 4 ). Surface-staining antibodies that were phycoerythrin (PE) conjugated were used at a dilution of 1:10, and the antibodies conjugated with FITC were used at a dilution of 1:5. For apoptosis analyses, we used annexin V, propidium iodide and 7-AAD (BD Biosciences).
Clonality analysis and spectratyping of B cell populations. We first amplified the entire repertoire of V H -DJ H gene rearrangements from B cell populations using PCR primers specific for the J558 V H -region gene together with a primer specific for the Cµ constant region. Next, using a FAM-conjugated Cµ constant region primer along with the J558 V H primer used in the previous step, we labeled our PCR products in a run-off reaction and subsequently analyzed them on a capillary sequencer (ABI3100, Applied Biosystems) by fragment-length analysis. Sequences of the primers used are given in Supplementary Table 5 .
Cloning of the murine stem cell virus (MSCV)-Bach2-ER T2 -IRES-GFP vector. We amplified Bach2 cDNA from the K562 cell line using the primers listed in Supplementary Table 5 . We then digested the cDNA using BamH1 and Xho1 and inserted it into the backbone obtained after digestion of the MSCV-Cre-ER T2 -IRES puromycin vector with BamH1 and Xho1. The vector obtained after this ligation was digested using BamH1 and EcoR1 to obtain the Bach2-ER T2 fragment. Finally, we ligated the Bach2-ER T2 fragment into a BglII-and EcoR1-digested MSCV-IRES-GFP vector.
Colony-forming assays. The methylcellulose colony-forming assays were performed with 10,000 BCR-ABL1-transformed Bach2 +/+ and Bach2 −/− cells or 10,000 c-Myc-IRES-GFP-transformed Bach2 +/+ and Bach2 −/− Il-7-dependent pre-B cells per group. For Myc-transduced Il-7-dependent cells, we performed the assay on OP9 stromal cells. Cells were resuspended in murine MethoCult medium (StemCell Technologies) and cultured on dishes (3 cm in diameter) with an extra water supply dish to prevent evaporation. We counted the colonies 7-14 d after plating.
Retroviral transduction.
We performed transfections of retroviral constructs and their corresponding empty vector controls ( Supplementary Table 6 ) using Lipofectamine 2000 (Invitrogen) with Opti-MEM medium (Invitrogen). We produced retroviral supernatants to infect mouse cells by cotransfecting HEK293FT cells with the plasmids pHIT60 (gag-pol) and pHIT123 (ecotropic envelope, provided by D.B. Kohn, University of California, Los Angeles, Los Angeles, CA).
To infect human cells, we replaced pHIT123 with pHIT456 (amphotropic envelope, provided by D.B. Kohn). We cultivated the cells in high-glucose DMEM (Invitrogen) with GlutaMAX containing 10% FBS, 100 IU ml −1 penicillin, 100 µg ml −1 streptomycin, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM sodium pyruvate and 0.1 mM of nonessential amino acids. We replaced the serum-free medium after 16 h with growth medium containing 10 mM sodium butyrate. After 8 h of incubation, we changed the medium back to growth medium. Twenty-four hours later, we harvested the viral supernatants, passing them through a 0.45-µm filter, and loaded them for centrifugation (2,000g for 90 min at 32 °C) twice on 50 µg ml −1 RetroNectin-coated nontissue culture-treated six-well plates. Two-to three-million pre-B cells were transduced per well by centrifugation at 600g for 30 min and maintained overnight at 37 °C with 5% CO 2 before transfer into culture flasks.
Cell-cycle analysis. For cell-cycle analysis of BCR-ABL1 ALL cells, we used the BrdU flow cytometry kit (BD Biosciences) according to the manufacturer's instructions. We measured BrdU incorporation (allophycocyanin (APC)labeled (552598) or GFP-labeled (559619) antibodies to BrdU (http://www. bdbiosciences.com/home.jsp), along with DNA content by 7-AAD, in fixed and permeabilized cells. We then gated the analysis on viable cells that were identified on the basis of scatter morphology.
Single-locus qChIP. ChIP assays were performed as previously described. Before ChIP, we briefly treated 1 × 10 7 BCR-ABL1-transformed mouse cells (Bach2 +/+ , Bach2 −/− or Bcl6 −/− ) with or without 2 µmol l −1 imatinib for 16 h. For BACH2 ChIP, primary human Ph + ALL cells (ICN1) were left untreated or were treated with 10 µmol l −1 imatinib for 24 h. Then the cells were crosslinked with 1% formaldehyde. After sonication by a bioruptor (Diagenode), we performed immunoprecipitations using 5 µg Bcl6 (C19, Santa Cruz Biotechnology, http:// www.scbt.com/), 5 µg BACH2 (a gift from the lab of A.M.) or control IgG antibody (Santa Cruz Biotechnology, http://www.scbt.com/). We washed the complexes with low-and high-salt buffers, eluted them, reverse crosslinked them and precipitated the DNA. We finally analyzed the immunoprecipitated DNA npg
